This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Soleno Therapeutics Vykat XR is now FDA approved for treating hyperphagia, or excessive hunger, in patients with Prader-Willi syndrome. The once-daily pill is the first approved therapy for this rare disease, a leading cause of childhood obesity.
Getting the correct food allergy diagnosis leads to increased diet diversity and potentially improved nutrition when suspected allergies are ruled out, making it critical to take the right diagnostic approach from the beginning.
Yet another study has been published showing that patients receiving care at PE-owned hospitals experienced a higher rate of hospital-acquired adverse events, like infections and falls, than patients receiving care at hospitals that are not PE-owned.
Results from the Phase 3 DREAMM-7 study show GSK drug Blenrep is helping multiple myeloma patients live longer compared to treatment with blockbuster Johnson & Johnson drug Darzalex. The post GSK Multiple Myeloma Drugs DREAMM Comeback Continues With Phase 3 Data at ASH appeared first on MedCity News.
Theseus Pharmaceuticals discontinued its former lead program in July following the report of dose-limiting toxicities in two patients. Though Theseus has other assets in its pipeline, it has decided to explore strategic alternatives with the goal of “maximizing shareholder value.”
Velatura, a leading multi-jurisdictional health information exchange and health data utility, along with Docusign, the leading intelligent agreement management solution that accelerates the process of doing business, have joined forces to streamline the process of obtaining and managing informed patient consent.
Here’s what is needed to create educational materials that empower patients and lead to better outcomes. The post Healthcare Needs to Be Proactive, Not Reactive — How Patient Education Improves Outcomes appeared first on MedCity News. Educational materials that are relatable and personalized can increase engagement.
The study, which was conducted by the startup, showed that the Luna Pathways program did a good job of reducing patients’ pain, increasing care plan adherence, and decreasing avoidable hospital readmissions and emergency department visits.
Hospitals are facing increasingly burdensome policies from commercial insurers, leading to problems with cash flow and patient safety. The post Payers Are Putting Profit Over Patients with Denials and Prior Auth Policies, Hospitals Say appeared first on MedCity News.
Continuous Glucose Monitoring tools are revolutionizing the way diabetes is managed, offering unparalleled benefits for both healthcare providers and patients. By providing continuous, accurate data, CGM is especially useful for remote monitoring, enabling timely interventions and leading to better user health.
Recognizing exceptional mental healthcare providers can lead to improved patient outcomes. Patients tend to have a better experience when they feel appreciated and valued. Acknowledging the efforts of mental healthcare providers can enhance the quality of care provided and, in turn, lead to better patient outcomes.
Value-based care depends on keeping a total population of patients healthier and less in need of higher-cost services. To do so, organizations must be able to predict costs in advance, better understand patient risks, and manage the cost of services. Corporate healthcare is set up to do just that.
Providers just aren’t given the time it takes to build rapport and ask the right questions within the fee-for-service model. That’s why I left traditional medicine. Providers like me who now work in an employer healthcare model can truly help people versus treating them reactively.
Called Microsoft Fabric, which was rolled out broadly in May, the announcement on October 10 marks the availability of Fabric’s capabilities specifically for the healthcare vertical – to clinicians, administrators but perhaps, most importantly, to patients. Lungs hyperinflated to clear. No pneumothorax or pleural eltusion.
FDA approval of Takeda Pharmaceutical drug Eohilia introduces a new therapeutic option for patients with eosinophilic esophagitis, inflammation of the esophagus that causes swallowing difficulty. It will compete against Dupixent, a Sanofi and Regeneron Pharmaceuticals drug already approved for this disorder.
Healthcare staffing shortages are leading to negative patient experiences, which is especially troublesome for small healthcare practices that often use good patient experiences to differentiate themselves from competitors, according to a new report.
A clinical trial for a Foghorn Therapeutics cancer drug is under a partial FDA hold after a patient in the early-stage study developed a cardiovascular complication. It’s the biotech’s second partial hold in the past year.
BioMarin Pharmaceutical’s submission of additional data for patients treated with its hemophilia A gene therapy, Roctavian, mean that the FDA will push out a regulatory decision to early summer. But it could be worth the wait as analysts anticipate FDA approval and project Roctavian becoming one of BioMarin’s biggest products.
Article by Richard Pops, CEO of Alkermes | Alkermes, a pioneer in neuroscience therapeutics, is building on its foundation as it emerges as a pure neuroscience company.
To position the healthcare system for long-term success, traditional healthcare providers must tap into new disruptive forces to create navigable, discoverable, accessible, and personalized experiences for patients who now expect a new consumer-centered model of care.
After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson & Johnson and Legend Biotech’ Carvykti has once again mounted a maj | After putting on a strong performance in preventing disease progression, Johnson & Johnson and Legend Biotech’s Carvykti has once again demonstrated (..)
By allowing study teams to design and conduct more inclusive and/or relevant studies, real-world data can enhance the standard of care and ultimately improve patient outcomes.
Ray Therapeutics’ gene therapy is independent of the causative genes driving inherited vision disorders, which CEO Paul Bresge says is important for reaching a broad patient population. Rare disease retinitis pigmentosa is the first disease target, but the startup also plans to test its approach in more prevalent eye disorders.
Santa Clara Valley Healthcare in California has begun notifying 43,000 patients about their eligibility for billing corrections and refunds. The system’s patient outreach effort is a result of a recently settled lawsuit filed against Santa Clara County.
IN BRIEF: Doctors are not required to treat obese patients who won’t do anything to lose weight but the problem is more than reminding patients they need to get exercise and drop pounds. This is leading to excessive costs to out healthcare system and something needs to be done. This is going to cost us ALL.
Situations like these can be an annoyance for neurotypical patients. For neurodivergent patients, they’re obstacles to getting adequate care. Eighty-five percent of medical students feel inadequately prepared to provide care for autistic patients. This will lead to better patient experiences and outcomes.
The FDA placed a partial clinical hold on late-stage tests of Sanofi multiple sclerosis drug tolebrutinib after some patients developed drug-induced liver injury. tests are paused, Sanofi said clinical testing in other countries is continuing with additional safety monitoring.
When the federal government enacted the No Surprises Act to lessen payment disputes between a patient or a health insurance plan and a provider, the government projected 22,000 disputes in 2022. However, between just April and September there were more than 90,000 disputes filed. .
Lowering patient out-of-pocket expenses through thoughtful plan design is not only beneficial for the patients but also for the healthcare system at large. The post Challenging Healthcare Norms: Early Access to Physical Therapy Transforms Musculoskeletal Care Delivery appeared first on MedCity News.
True patient engagement creates ripple effects that transform both clinical outcomes and business results in a measurable way. Measuring engagement isnt just about numbersits about the lives that are touched and the improvements made through strategic, thoughtful approaches to patient communication.
Lack of access to care and unaddressed SDOH issues lead to poorly managed chronic conditions, delays in treatment, medication non-adherence, and lower utilization of preventive services. Poverty significantly impacts the mental and physical health of older adults.
Hear from patients, leading provider and payer executives, investors, and healthcare startups about how to improve the patient experience at the event, which kicks off the first day of the HLTH conference. ENGAGE at HLTH is scheduled for November 13 at the Venetian Expo in Las Vegas.
When pharmacies engage on a human level with patient support programs, patients become more fully engaged in their treatment, leading to potentially significant health benefits and good business for pharmacies.
Do patients care? Do patients care? If you’re a cancer patient and your oncologist is prescribing a drug approved via accelerated Approval, are you going to refuse treatment? Should patients be made aware that the drug they are being prescribed is an “accelerated approval drug”? Of course not.
Automation, AI, and machine learning can all be used to identify issues that lead to denials, streamline the patient billing process, reduce manual processes, and provide real-time data to quickly process claims.
And, it can increase patient volume and revenue. And when woven into your content marketing strategy, a strong value proposition becomes essential for increasing patient volume and revenue in the healthcare industry. That’s why your value proposition is crucial for attracting new patients and ensuring long-term loyalty.
Deeply Understand Your Market and Audience To create a leading product, you need to understand the therapeutic area thoroughly. Equally important is understanding your target audience—patients, healthcare professionals, regulators, and payers. Invest in strategies that allow you to engage healthcare professionals and patients directly.
HHS recently released a final rule that allows practitioners in Opioid Treatment Programs to start patients on methadone or buprenorphine via telehealth. However, the final rule does not apply to the broader range of providers, leading telehealth advocates to call for additional changes from the DEA.
A health system’s failure to offer patients with digital payment options could lead to slower collection times, create a disjointed patient financial experience, and result in decreased patient satisfaction and loyalty.
This decrease could lead to increased costs and decreased efficiency for healthcare systems as well as decreased access and poorer health outcomes for patients if nothing is done about it soon.
Imagine a time when pharmaceutical ads simply told patients what to ask their doctor. Today, patient marketing is no longer a one-way street. This article dives deep into how patient marketing has changed, whats driving this transformation, and what strategies are leading the way for 2025 and beyond.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content